View More View Less
  • 1 Pécsi Tudományegyetem, Klinikai Központ I. Belgyógyászati Klinika Pécs Ifjúság u. 13. 7624
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az acromegalia ritka, jellegzetes klinikai képpel járó kórkép, amely hosszú távon 2–4-szeres mortalitásnövekedést okoz. Kezelésének célja kettős: az úgynevezett biokémiai kontroll elérése (IGF-1-szint a nemnek, kornak megfelelő normális tartományban, GH-szint OGTT során 1 ng/ml alatt, random GH 2,5 ng/ml alatt) és a tumormassza csökkentése/eliminációja. A kezelés jelenlegi lehetőségei az idegsebészeti beavatkozás, a gyógyszeres kezelés és a radioterápia, valamint ezek kombinációi. A gyógyszeres kezelés sarokkövét acromegaliában a szomatosztatinreceptor-ligandok jelentik, mivel a növekedésihormon-szekréciót a betegek 60–70%-ában kontrollálják, és a hypophysis tumorméretére is jótékony hatással bírnak. Legtöbbször műtét után, adjuváns kezelésként alkalmazzák, de szelektált beteganyagon egyre több bizonyíték támogatja a primer szomatosztatinanalóg-terápiát. Tartós alkalmazásuk biztonságos, mellékhatásprofiljuk alapján jól tolerálható készítmények. A jövő gyógyszeres kezelési lehetőségei közé tartozik a pasireotid, egy új, univerzális szomatosztatinreceptor-agonista, illetve egy új gyógyszercsoport, az úgynevezett dopastatinok. Az irodalomban kiméramolekuláknak nevezett utóbbi szerek egyszerre hatnak a dopamin- és szomatosztatinreceptorokon, ezáltal az előzetes adatok szerint erőteljesebben csökkentik a GH-szekréciót. A közleményben a szerzők az acromegalia korszerű gyógyszeres kezelési lehetőségeit tekintik át, kiemelve a szomatosztatinreceptor-ligandok szerepét. Orv. Hetil., 2011, 152, 715–721.

  • Etxabe, J., Gaztambide, S., Latorrem P. és mtsa: Acromegaly: an epidemiological study. J. Endocrinol. Invest., 1993, 16, 181–187.

    Latorrem P. , 'Acromegaly: an epidemiological study ' (1993 ) 16 J. Endocrinol. Invest. : 181 -187.

    • Search Google Scholar
  • Holdaway, I. M., Rajasoorya, C.: Epidemiology of acromegaly. Pituitary, 1999, 2, 29–41.

    Rajasoorya C. , 'Epidemiology of acromegaly ' (1999 ) 2 Pituitary : 29 -41.

  • Daly, A. F., Rixhon, M., Adam, C. és mtsai: High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab., 2006, 91, 4769–4775.

    Adam C. , 'High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 4769 -4775.

    • Search Google Scholar
  • Biermasz, N. R., Smit, J. W., Pereira, A. M. és mtsai: Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary, 2007, 10, 237–249.

    Pereira A. M. , 'Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients ' (2007 ) 10 Pituitary : 237 -249.

    • Search Google Scholar
  • Orme, S. M., McNally, R. J., Cartwright, R. A. és mtsa: Mortality and cancer incidence in acromegaly: a retrospecitve cohort study. UK Acromegaly Study Group. J. Clin. Endocrinol. Metab., 1998, 83, 2730–2734.

    Cartwright R. A. , 'Mortality and cancer incidence in acromegaly: a retrospecitve cohort study. UK Acromegaly Study Group ' (1998 ) 83 J. Clin. Endocrinol. Metab. : 2730 -2734.

    • Search Google Scholar
  • Loeper, S., Ezzat, S.: Acromegaly: re-thinking the cancer risk. Rev. Endocr. Metab. Disord., 2008, 9, 41–58.

    Ezzat S. , 'Acromegaly: re-thinking the cancer risk ' (2008 ) 9 Rev. Endocr. Metab. Disord. : 41 -58.

    • Search Google Scholar
  • Giustina, A., Chanson, P., Bronstein, M. D. és mtsai: A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab., 2010, 95, 3141–3148.

    Bronstein M. D. , 'A consensus on criteria for cure of acromegaly ' (2010 ) 95 J. Clin. Endocrinol. Metab. : 3141 -3148.

    • Search Google Scholar
  • Czirják S.: A növekedési hormont termelő hypophysis adenomák korszerű diagnosztikája és kezelése. LAM, 2006, 16, 707–714.

    Czirják S. , 'A növekedési hormont termelő hypophysis adenomák korszerű diagnosztikája és kezelése ' (2006 ) 16 LAM : 707 -714.

    • Search Google Scholar
  • Cozzi, R., Attanasim, R., Lodrini, S. és mtsa: Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf), 2004, 61, 209–215.

    Lodrini S. , 'Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status ' (2004 ) 61 Clin. Endocrinol. (Oxf) : 209 -215.

    • Search Google Scholar
  • Schopohl, J., Strasburger, C. J., Caird, D. és mtsai: Efficacy and acceptability of lanreotide autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes, 2011, 119, 156–162.

    Caird D. , 'Efficacy and acceptability of lanreotide autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR ' (2011 ) 119 Exp. Clin. Endocrinol. Diabetes : 156 -162.

    • Search Google Scholar
  • Freda, P. U., Katznelson, L., van der Lely, A. J. és mtsai: Long acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab., 2005, 90, 4465–4473.

    Lely A. J. , 'Long acting somatostatin analog therapy of acromegaly: a meta-analysis ' (2005 ) 90 J. Clin. Endocrinol. Metab. : 4465 -4473.

    • Search Google Scholar
  • Andries, M., Glintborg, D., Kvisborg, A. és mtsai: A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin. Endocrinol. (Oxf), 2008, 68, 473–480.

    Kvisborg A. , 'A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly ' (2008 ) 68 Clin. Endocrinol. (Oxf) : 473 -480.

    • Search Google Scholar
  • Mercado, M., Borges, F., Bouterfa, H. et al., SMS995B2401 Study Group: A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (longacting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. (Oxf), 2007, 66, 859–868.

    Bouterfa H. , 'A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (longacting repeatable octreotide) in the primary therapy of patients with acromegaly ' (2007 ) 66 Clin. Endocrinol. (Oxf) : 859 -868.

    • Search Google Scholar
  • Ronchi, C. L., Boschetti, M., Uberti, E. C. és mtsai: Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin. Endocrinol. (Oxf), 2007, 67, 512–519.

    Uberti E. C. , 'Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study ' (2007 ) 67 Clin. Endocrinol. (Oxf) : 512 -519.

    • Search Google Scholar
  • Alexopoulou, O., Abrams, P., Verhelst, J. és mtsai: Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur. J. Endocrinol., 2004, 151, 317–324.

    Verhelst J. , 'Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR ' (2004 ) 151 Eur. J. Endocrinol. : 317 -324.

    • Search Google Scholar
  • Ashwell, S. G., Bevan, J. S., Edwards, O. M. és mtsai: The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur. J. Endocrinol., 2004, 150, 473–480.

    Edwards O. M. , 'The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR ' (2004 ) 150 Eur. J. Endocrinol. : 473 -480.

    • Search Google Scholar
  • Murray, R. D., Melmed, S.: A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metab., 2008, 93, 2957–2968.

    Melmed S. , 'A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly ' (2008 ) 93 J. Clin. Endocrinol. Metab. : 2957 -2968.

    • Search Google Scholar
  • Colao, A., Auriemma, R. S., Galdiero, M. és mtsai: Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-1 levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab., 2009, 94, 3746–3756.

    Galdiero M. , 'Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-1 levels, tumor shrinkage, and cardiovascular disease: a prospective study ' (2009 ) 94 J. Clin. Endocrinol. Metab. : 3746 -3756.

    • Search Google Scholar
  • Bevan, J. S.: Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab., 2005, 90, 1856–1863.

    Bevan J. S. , 'Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly ' (2005 ) 90 J. Clin. Endocrinol. Metab. : 1856 -1863.

    • Search Google Scholar
  • Melmed, S., Sternberg, R., Cook, D. és mtsai: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab., 2005, 90, 4405–4410.

    Cook D. , 'A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly ' (2005 ) 90 J. Clin. Endocrinol. Metab. : 4405 -4410.

    • Search Google Scholar
  • Manjila, S., Wu, O. C., Khan, F. R. és mtsai: Pharmacological management of acromegaly: A current perspective. Neurosurg. Focus, 2010, 29, e14.

    Khan F. R. , 'Pharmacological management of acromegaly: A current perspective ' (2010 ) 29 Neurosurg. Focus : e14 -.

    • Search Google Scholar
  • Mazziotti, G., Giustina, A.: Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary, 2010, 13, 60–67.

    Giustina A. , 'Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review ' (2010 ) 13 Pituitary : 60 -67.

    • Search Google Scholar
  • Amato, G., Mazziotti, G., Rotondi, M. és mtsai: Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin. Endocrinol. (Oxf), 2002, 56, 65–71.

    Rotondi M. , 'Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly ' (2002 ) 56 Clin. Endocrinol. (Oxf) : 65 -71.

    • Search Google Scholar
  • Casarini, A. P., Pinto, E. M., Jallad, R. S. és mtsai: Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J. Endocrinol. Invest., 2006, 29, 826–830.

    Jallad R. S. , 'Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3 ' (2006 ) 29 J. Endocrinol. Invest. : 826 -830.

    • Search Google Scholar
  • Resmini, E., Dadati, P., Ravetti, J. L. és mtsai: Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J. Clin. Endocrinol. Metab., 2007, 92, 1592–1599.

    Ravetti J. L. , 'Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient ' (2007 ) 92 J. Clin. Endocrinol. Metab. : 1592 -1599.

    • Search Google Scholar
  • Lamberts, S. W., van der Lely, A. J., de Herder, W. W. és mtsa: Octreotide. N. Engl. J. Med., 1996, 334, 246–254.

    Herder W. W. , 'Octreotide ' (1996 ) 334 N. Engl. J. Med. : 246 -254.

  • Florio, T., Thellung, S., Corsaro, A. és mtsai: Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin. Endocrinol. (Oxf), 2003, 59, 115–128.

    Corsaro A. , 'Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro ' (2003 ) 59 Clin. Endocrinol. (Oxf) : 115 -128.

    • Search Google Scholar
  • Gola, M., Bonadonna, S., Mazziotti, G. és mtsai: Resistance to somatostatin analogs in acromegaly: an evolving concept? J. Endocrinol. Invest., 2006, 29, 86–93.

    Mazziotti G. , 'Resistance to somatostatin analogs in acromegaly: an evolving concept? ' (2006 ) 29 J. Endocrinol. Invest. : 86 -93.

    • Search Google Scholar
  • Baldelli, R., Battista, C., Leonetti, F. és mtsai: Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin. Endocrinol. (Oxf), 2003, 59, 492–499.

    Leonetti F. , 'Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment ' (2003 ) 59 Clin. Endocrinol. (Oxf) : 492 -499.

    • Search Google Scholar
  • Wuster, C., Both, S., Cordes, U. és mtsai: Primary treatment of acromegaly with high-dose lanreotide: a case series. J. Med. Case Reports, 2010, 4, 85.

    Cordes U. , 'Primary treatment of acromegaly with high-dose lanreotide: a case series ' (2010 ) 4 J. Med. Case Reports : 85 -.

    • Search Google Scholar
  • Giustina, A., Bonadonna, S., Bugari, G. és mtsai: High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol., 2009, 161, 331–338.

    Bugari G. , 'High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial ' (2009 ) 161 Eur. J. Endocrinol. : 331 -338.

    • Search Google Scholar
  • Cozzi, R., Attanasio, R., Montini, M. és mtsai: Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab., 2003, 88, 3090–3098.

    Montini M. , 'Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? ' (2003 ) 88 J. Clin. Endocrinol. Metab. : 3090 -3098.

    • Search Google Scholar
  • Lancranjan, I., Atkinson, A. B.: Results of a European multicenter study with Sandostatin LAR in acromegalic patients. Sandostatin LA group. Pituitary, 1999, 1, 105–114.

    Atkinson A. B. , 'Results of a European multicenter study with Sandostatin LAR in acromegalic patients. Sandostatin LA group ' (1999 ) 1 Pituitary : 105 -114.

    • Search Google Scholar
  • Colao, A., Pivonello, R., Rosato, F. és mtsai: First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin. Endocrinol. (Oxf), 2006, 64, 342–351.

    Rosato F. , 'First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial ' (2006 ) 64 Clin. Endocrinol. (Oxf) : 342 -351.

    • Search Google Scholar
  • Giusti, M., Ciccarelli, E., Dallabonzana, D. és mtsai: Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur. J. Clin. Invest., 1997, 27, 277–284.

    Dallabonzana D. , 'Clinical results of long-term slow-release lanreotide treatment of acromegaly ' (1997 ) 27 Eur. J. Clin. Invest. : 277 -284.

    • Search Google Scholar
  • Caron, P., Morange-Ramos, I., Cogne, M. és mtsa: Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab., 1997, 82, 18–22.

    Cogne M. , 'Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide ' (1997 ) 82 J. Clin. Endocrinol. Metab. : 18 -22.

    • Search Google Scholar
  • Fleseriu, M.: Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary, 2010. Dec 15. (Epub ahead of print.)

  • Colao, A., Lombardi, G.: Dose optimization of somatostatin analogues for acromegaly patients. J. Endocrinol. Invest., 2010, 33, 125–127.

    Lombardi G. , 'Dose optimization of somatostatin analogues for acromegaly patients ' (2010 ) 33 J. Endocrinol. Invest. : 125 -127.

    • Search Google Scholar
  • Feelders, R. A., Hofland, L. J., van Aken, M. O. és mtsai: Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs, 2009, 69, 2207–2226.

    Aken M. O. , 'Medical therapy of acromegaly: efficacy and safety of somatostatin analogues ' (2009 ) 69 Drugs : 2207 -2226.

    • Search Google Scholar
  • Attanasio, R., Lanzi, R., Losa, M. és mtsai: Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr. Pract., 2008, 14, 846–855.

    Losa M. , 'Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study ' (2008 ) 14 Endocr. Pract. : 846 -855.

    • Search Google Scholar
  • Colao, A., Pivonello, R., Auriemma, R. S. és mtsai: Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur. J. Endocrinol., 2007, 157, 579–587.

    Auriemma R. S. , 'Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly ' (2007 ) 157 Eur. J. Endocrinol. : 579 -587.

    • Search Google Scholar
  • Colao, A., Auriemma, R. S., Rebora, A. és mtsai: Significant tumour shrinkage after 12 months of lanreotide Autogel 120 mg treatment given first-line in acromegaly. Clin. Endocrinol. (Oxf), 2009, 71, 237–245.

    Rebora A. , 'Significant tumour shrinkage after 12 months of lanreotide Autogel 120 mg treatment given first-line in acromegaly ' (2009 ) 71 Clin. Endocrinol. (Oxf) : 237 -245.

    • Search Google Scholar
  • Mao, Z. G., Zhu, Y. H., Tang, H. L. és mtsai: Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol., 2010, 162, 661–666.

    Tang H. L. , 'Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial ' (2010 ) 162 Eur. J. Endocrinol. : 661 -666.

    • Search Google Scholar
  • Cozzi, R., Montini, M., Attanasio, R. és mtsai: Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metab., 2006, 91, 1397–1403.

    Attanasio R. , 'Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 1397 -1403.

    • Search Google Scholar
  • Melmed, S.: Medical progress: acromegaly. N. Engl. J. Med., 2006, 355, 2558–2573.

    Melmed S. , 'Medical progress: acromegaly ' (2006 ) 355 N. Engl. J. Med. : 2558 -2573.

  • Van der Hoek, J., de Herder, W. W., Feelders, R. A. és mtsai: A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J. Clin. Endocrinol. Metab., 2004, 89, 638–645.

    Feelders R. A. , 'A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients ' (2004 ) 89 J. Clin. Endocrinol. Metab. : 638 -645.

    • Search Google Scholar
  • Van der Hoek, J., van der Lelij, A. J., Feelders, R. A. és mtsai: The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin. Endocrinol. (Oxf), 2005, 63, 176–184.

    Feelders R. A. , 'The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients ' (2005 ) 63 Clin. Endocrinol. (Oxf) : 176 -184.

    • Search Google Scholar
  • Farrall, A., Glusman, J. E., Buchelt, A. és mtsai: Pasireotide (SOM 230) effectively reduces pituitary tumor volume in patients with active acromegaly: results from a Phase II trial. Presented at ENDO 2007, abst., OR53-4.

  • Lattuada, D., Casnici, C., Crotta, K. és mtsai: Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J. Neuroimmunol., 2007, 182, 153–159.

    Crotta K. , 'Inhibitory effect of pasireotide and octreotide on lymphocyte activation ' (2007 ) 182 J. Neuroimmunol. : 153 -159.

    • Search Google Scholar
  • Fedele, M., De Martino, I., Pivonello, R.: SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin. Cancer. Res., 2007, 13, 2738–2744.

    Pivonello R. , 'SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas ' (2007 ) 13 Clin. Cancer. Res. : 2738 -2744.

    • Search Google Scholar
  • Adams, R. L., Adams, I. P., Lindow, S. W. és mtsa: Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin. Endocrinol. (Oxf), 2004, 61, 431–436.

    Lindow S. W. , 'Inhibition of endothelial proliferation by the somatostatin analogue SOM230 ' (2004 ) 61 Clin. Endocrinol. (Oxf) : 431 -436.

    • Search Google Scholar
  • Saveanu, A., Jaquet, P., Brue, T. és mtsa: Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol. Cell. Endocrinol., 2008, 286, 206–213.

    Brue T. , 'Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas ' (2008 ) 286 Mol. Cell. Endocrinol. : 206 -213.

    • Search Google Scholar
  • Saveanu, A., Gunz, G., Guillen, S. és mtsai: Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology, 2006, 83, 258–263.

    Guillen S. , 'Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas ' (2006 ) 83 Neuroendocrinology : 258 -263.

    • Search Google Scholar
  • Jaquet, P., Gunz, G., Saveanu, A. és mtsai: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol., 2005, 153, 135–141.

    Saveanu A. , 'Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy ' (2005 ) 153 Eur. J. Endocrinol. : 135 -141.

    • Search Google Scholar